Retatrutide Reconstitution and Dosing
For a 2mg dose of Retatrutide, you will need 0.1mL of the reconstituted solution.
Reconstitution Calculation
When you add 3mL of bacteriostatic water to a 60mg vial of Retatrutide powder, you create a solution with the following concentration:
- Total Retatrutide: 60mg
- Total volume: 3mL
- Concentration: 60mg ÷ 3mL = 20mg/mL
Therefore, for a 2mg dose:
- Dose needed: 2mg
- Volume required: 2mg ÷ 20mg/mL = 0.1mL
Administration Guidelines
- Use a small insulin syringe with 0.01mL markings for accurate measurement
- Administer subcutaneously once weekly as per clinical trial protocols
- Common injection sites include abdomen, thigh, or upper arm
Clinical Context
Retatrutide is a triple-hormone-receptor agonist that targets:
- Glucose-dependent insulinotropic polypeptide (GIP) receptor
- Glucagon-like peptide-1 (GLP-1) receptor
- Glucagon receptor
Recent clinical trials have shown that Retatrutide produces substantial weight reduction in adults with obesity, with dose-dependent effects 1. In a phase 2 trial, participants receiving various doses of Retatrutide (1mg to 12mg) experienced weight reductions ranging from 8.7% to 24.2% after 48 weeks of treatment 1.
Important Considerations
- Proper reconstitution technique is essential to maintain drug stability and sterility
- Bacteriostatic water contains preservatives that allow for multiple withdrawals from the same vial
- Store reconstituted solution according to manufacturer's instructions (typically refrigerated)
- Discard any unused medication after the recommended storage period
Common Side Effects
The most common adverse events reported in clinical trials were gastrointestinal in nature:
- Nausea
- Diarrhea
- Vomiting
- Constipation
These side effects were generally mild to moderate in severity and partially mitigated with lower starting doses 1, 2.
Monitoring Recommendations
- Monitor for gastrointestinal side effects, especially during dose initiation and escalation
- Be aware of potential heart rate increases, which were observed to peak at 24 weeks and decline thereafter in clinical trials 1
- Regular assessment of weight, glycemic control, and other metabolic parameters is recommended
Always ensure proper handling of injectable medications and follow aseptic technique when reconstituting and administering Retatrutide to minimize risk of contamination.